Patents Assigned to MYR GMBH
  • COMBINATION THERAPY OF HBV AND HDV INFECTION
    Publication number: 20220040178
    Abstract: The invention provides a composition comprising an inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) and a active ingredient selected from the group consisting of a nucleoside analogue such as lamivudine, telbivudine, or entecavir, a nucleotide analogue such as tenofovir, adefovir and an immunomodulator such as interferon alpha. The NTCP inhibitor inhibits HBV/HDV entry into a cell and is preferably derived from an HBV pre-S1 peptide. Also provided are methods of treating HBV and HDV infection, hepatitis B and D, or chronic hepatitis B and D.
    Type: Application
    Filed: March 23, 2021
    Publication date: February 10, 2022
    Applicant: MYR GMBH
    Inventor: Alexander ALEXANDROV
  • THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS
    Publication number: 20210196786
    Abstract: An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 1, 2021
    Applicant: MYR GmbH
    Inventor: Alexander ALEXANDROV
  • Therapy of atherosclerosis, primary biliary cirrhosis and NRLP3 inflammasome-associated disease by HTCP inhibitors
    Patent number: 10925925
    Abstract: An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: February 23, 2021
    Assignee: MYR GMBH
    Inventor: Alexander Alexandrov
  • THERAPY OF ATHEROSCLEROSIS, PRIMARY BILIARY CIRRHOSIS AND NRLP3 INFLAMMASOME-ASSOCIATED DISEASE BY HTCP INHIBITORS
    Publication number: 20180296634
    Abstract: An inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) for use in a method of treatment of primary biliary cirrhosis, atherosclerosis, or an NRLP3 inflammasome-associated disease in a subject.
    Type: Application
    Filed: April 12, 2018
    Publication date: October 18, 2018
    Applicant: MYR GmbH
    Inventor: Alexander ALEXANDROV
  • COMBINATION THERAPY OF HBV AND HDV INFECTION
    Publication number: 20180228804
    Abstract: The invention provides a composition comprising an inhibitor of Na+-taurocholate cotransporting polypeptide (NTCP) and a active ingredient selected from the group consisting of a nucleoside analogue such as lamivudine, telbivudine, or entecavir, a nucleotide analogue such as tenofovir, adefovir and an immunomodulator such as interferon alpha. The NTCP inhibitor inhibits HBV/HDV entry into a cell and is preferably derived from an HBV pre-S1 peptide. Also provided are methods of treating HBV and HDV infection, hepatitis B and D, or chronic hepatitis B and D.
    Type: Application
    Filed: October 7, 2015
    Publication date: August 16, 2018
    Applicant: MYR GMBH
    Inventor: Alexander ALEXANDROV